Lifecore Biomedical, Inc. cash flow to debt ratio of 8.81% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lifecore Biomedical, Inc.'s free cash flow has increased 145.74% from $-13.62M last year to $6.23M, signaling increasing performance

Lifecore Biomedical, Inc.'s debt to equity ratio is 9.64, which means that the company's assets are unhealthy financed, signaling financial risk.

Lifecore Biomedical, Inc.'s debt has decreased relative to shareholder equity from 11.81 last year to 9.64 today, signaling strengthened financials

Lifecore Biomedical, Inc. has a net debt to EBITDA ratio of 15.18x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Lifecore Biomedical, Inc.'s interest coverage ratio is -0.09, which means that the company struggles to meet interest obligations, signaling financial risk.

Lifecore Biomedical, Inc.'s profit margin was -30.04% last year and is -30.40% this year, signaling decreasing performance

Lifecore Biomedical, Inc.'s short-term assets of $82.29M exceed its short-term liabilities of $23.57M

Lifecore Biomedical, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lifecore Biomedical, Inc.'s return on equity of -376.95%, is lower than 15.00%, indicating bad performance

Lifecore Biomedical, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lifecore Biomedical, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Lifecore Biomedical, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Lifecore Biomedical, Inc. has a free cash flow yield of 3.95%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Lifecore Biomedical, Inc.'s yearly earnings has increased 20.47% since last year from $-38.72M to $-30.79M, signaling increasing performance

Lifecore Biomedical, Inc.'s yearly revenue has increased 0.46% since last year from $128.87M to $129.46M, signaling increasing performance

ROIC -1.25% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lifecore Biomedical, Inc.'s 3-year revenue CAGR of 7.83% is positive, indicating growing revenue over the past 3 years

Lifecore Biomedical, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Lifecore Biomedical, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Lifecore Biomedical, Inc. has insufficient data to evaluate this check.

Lifecore Biomedical, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lifecore Biomedical, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Lifecore Biomedical, Inc. has an EV/EBITDA ratio of 34.30x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Lifecore Biomedical, Inc. has insufficient data to evaluate this check.

Lifecore Biomedical, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lifecore Biomedical, Inc. has a price-to-book ratio of 9.81x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Lifecore Biomedical, Inc. has a price-to-sales ratio of 1.29x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue